SubsidieMeesters logoSubsidieMeesters
ProjectenRegelingenAnalyses

TACKLING FUNCTIONAL MATURATION FOR TRANSPLANTABLE HEMATOPOIETIC STEM CELL GENERATION

FUN-HSC aims to identify and mimic maturation pathways of hematopoietic stem cells from pluripotent stem cells to create a reliable, clinically valuable source for diverse therapies.

Subsidie
€ 2.265.684
2024

Projectdetails

Introduction

Hematopoietic stem cells (HSC) provide a lifelong supply of blood and immune cells. They are a life-saving therapy for leukemia and have recently found broadened applications to gene and cell therapy, against other cancers, genetic, autoimmune, and infectious diseases.

Challenges in HSC Therapy

Nonetheless, practical limitations, such as donor-matching or insufficient cell number, render these therapies unfeasible or unsuccessful for many patients. Attempts to overcome these limitations have been unable to create a reliable source of HSC for patients.

Current Research on HSC Generation

While we can generate human HSC from pluripotent stem cells (PSC), they resemble early development stages, lacking the functional maturation hallmarks. FUN-HSC aims at identifying core and actionable maturation pathways for HSCs and at defining the contribution of coordinated gene expression by chromatin regulation, using a combination of functional and genetic screening technologies and high-throughput readouts in vitro and in vivo.

HSC Maturation Process

HSC maturation occurs in the liver during fetal development and confers functional multilineage hematopoiesis ability throughout adulthood. Using single cell omics analysis of human embryonic and fetal tissues, we describe multiple gene programs changing during developmental HSC maturation.

Research Methodology

This study will lead to candidate cell-intrinsic and niche-dependent instructions, which will be dissected in the context of the fetal liver by:

  1. Analyzing the cell compartments and their interactions.
  2. Combining novel organoid technologies with mouse xenografts to model the fetal liver environment.

Future Goals

Ultimately, we aim to identify a strategy that mimics these pathways in vitro to bring the maturation stage of the PSC-derived HSC to a robustly engraftable and clinically valuable HSC source.

Conclusion

Harnessing new knowledge in human HSC biology, cutting-edge genetics, and tissue technologies, FUN-HSC will provide great advances in the mission of making and maintaining HSCs in vitro, enabling their full therapeutic potential.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.265.684
Totale projectbegroting€ 2.265.684

Tijdlijn

Startdatum1-1-2024
Einddatum31-12-2028
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERASpenvoerder
  • UNIVERSITY COLLEGE LONDON

Land(en)

SpainUnited Kingdom

Inhoudsopgave

European Research Council

Financiering tot €10 miljoen voor baanbrekend frontier-onderzoek via ERC-grants (Starting, Consolidator, Advanced, Synergy, Proof of Concept).

Bekijk regeling

Vergelijkbare projecten binnen European Research Council

ProjectRegelingBedragJaarActie

Dissecting the molecular regulation of hematopoietic stem cell emergence using pluripotent stem cells to improve ex vivo therapies

This project aims to develop methods for generating and expanding hematopoietic stem cells from patient-specific induced pluripotent stem cells to overcome transplantation barriers and enhance therapies.

ERC Consolid...€ 2.000.000
2023
Details

How is blood (re-)made? Regeneration of human hematopoietic stem cells after transplantation

RESTART aims to enhance survival in pediatric HSCT by using multiomics to characterize human HSPC regeneration and identify predictors of adverse outcomes.

ERC Starting...€ 1.500.000
2024
Details

Dissecting hepatocyte heterogeneity in liver growth to devise liver gene therapies for pediatric patients

HEPAGENE aims to understand hepatocyte heterogeneity and its role in liver growth to develop safe, effective gene therapies for pediatric metabolic diseases through advanced genetic engineering techniques.

ERC Consolid...€ 1.993.750
2025
Details

The impact of human aged bone marrow niche on human hematopoietic stem cell function

This project aims to investigate how aging alters the human bone marrow niche and its impact on hematopoietic stem cell function to improve understanding and outcomes in elderly hematopoiesis.

ERC Starting...€ 1.500.000
2025
Details

Origins and Consequences of Hematopoietic Stem Cell Memories

MemOriStem aims to uncover the origins and mechanisms of hematopoietic stem cell memories to enhance regenerative therapies for chronic inflammation, aging, and cancer.

ERC Starting...€ 1.500.000
2022
Details
ERC Consolid...

Dissecting the molecular regulation of hematopoietic stem cell emergence using pluripotent stem cells to improve ex vivo therapies

This project aims to develop methods for generating and expanding hematopoietic stem cells from patient-specific induced pluripotent stem cells to overcome transplantation barriers and enhance therapies.

ERC Consolidator Grant
€ 2.000.000
2023
Details
ERC Starting...

How is blood (re-)made? Regeneration of human hematopoietic stem cells after transplantation

RESTART aims to enhance survival in pediatric HSCT by using multiomics to characterize human HSPC regeneration and identify predictors of adverse outcomes.

ERC Starting Grant
€ 1.500.000
2024
Details
ERC Consolid...

Dissecting hepatocyte heterogeneity in liver growth to devise liver gene therapies for pediatric patients

HEPAGENE aims to understand hepatocyte heterogeneity and its role in liver growth to develop safe, effective gene therapies for pediatric metabolic diseases through advanced genetic engineering techniques.

ERC Consolidator Grant
€ 1.993.750
2025
Details
ERC Starting...

The impact of human aged bone marrow niche on human hematopoietic stem cell function

This project aims to investigate how aging alters the human bone marrow niche and its impact on hematopoietic stem cell function to improve understanding and outcomes in elderly hematopoiesis.

ERC Starting Grant
€ 1.500.000
2025
Details
ERC Starting...

Origins and Consequences of Hematopoietic Stem Cell Memories

MemOriStem aims to uncover the origins and mechanisms of hematopoietic stem cell memories to enhance regenerative therapies for chronic inflammation, aging, and cancer.

ERC Starting Grant
€ 1.500.000
2022
Details

Vergelijkbare projecten uit andere regelingen

ProjectRegelingBedragJaarActie

Exploiting ex vivo expansion and deep multiomics profiling to bring novel, efficient and safer hematopoietic stem cell gene therapies to clinical application

This project aims to innovate hematopoietic stem cell identification and engineering through advanced culture techniques and multiomics profiling, enhancing gene therapy for blood disorders and cancer.

EIC Pathfinder€ 3.797.562
2022
Details

NOn-VIral gene modified STEM cell therapy

This project aims to develop a high-throughput protocol for producing gene-corrected CAR T cells and blood stem cells using optimized photoporation and CRISPR technology for enhanced clinical application.

EIC Pathfinder€ 3.644.418
2022
Details

AI-powered platform for autologous iPSC manufacturing

The project aims to develop an AI-guided microfluidic device for the standardized, cost-effective mass production of personalized iPSCs to enhance cancer therapies and tissue regeneration.

EIC Pathfinder€ 3.999.225
2022
Details

PEN photoporation for the genetic engineering of therapeutic mesenchymal stromal cells and T cells

This project aims to develop an automated high-throughput PEN photoporation system for safely and efficiently genetically modifying T cells and MSCs for cancer therapy commercialization.

EIC Transition€ 2.497.711
2024
Details
EIC Pathfinder

Exploiting ex vivo expansion and deep multiomics profiling to bring novel, efficient and safer hematopoietic stem cell gene therapies to clinical application

This project aims to innovate hematopoietic stem cell identification and engineering through advanced culture techniques and multiomics profiling, enhancing gene therapy for blood disorders and cancer.

EIC Pathfinder
€ 3.797.562
2022
Details
EIC Pathfinder

NOn-VIral gene modified STEM cell therapy

This project aims to develop a high-throughput protocol for producing gene-corrected CAR T cells and blood stem cells using optimized photoporation and CRISPR technology for enhanced clinical application.

EIC Pathfinder
€ 3.644.418
2022
Details
EIC Pathfinder

AI-powered platform for autologous iPSC manufacturing

The project aims to develop an AI-guided microfluidic device for the standardized, cost-effective mass production of personalized iPSCs to enhance cancer therapies and tissue regeneration.

EIC Pathfinder
€ 3.999.225
2022
Details
EIC Transition

PEN photoporation for the genetic engineering of therapeutic mesenchymal stromal cells and T cells

This project aims to develop an automated high-throughput PEN photoporation system for safely and efficiently genetically modifying T cells and MSCs for cancer therapy commercialization.

EIC Transition
€ 2.497.711
2024
Details

SubsidieMeesters logoSubsidieMeesters

Vind en verken subsidieprojecten in Nederland en Europa.

Links

  • Projecten
  • Regelingen
  • Analyses

Suggesties

Heb je ideeën voor nieuwe features of verbeteringen?

Deel je suggestie
© 2025 SubsidieMeesters. Alle rechten voorbehouden.